Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen says new data supports cancer treatment options

Amgen says new data supports cancer treatment options

18th May 2009

Amgen believes its latest research findings support certain methods for the treatment of cancer and its side effects.

The company, which is due to present data later this month, said the scientific view that growth regulation, angiogenesis, apoptosis, bone metabolism and haematopoiesis pathways could be used is sustained by the studies.

According to Amgen’s global development head and chief medical officer Sean Harper, the results have furthered the company’s understanding of biological and clinical effects of key molecules.

He added: “The clinical benefits and safety profiles of some of these molecules will be further evaluated when results from four phase III oncology studies and five phase II programmes across multiple tumour types are unveiled by the end of this year.”

The news follows a statement from Amgen last month that detailed research on several preclinical studies into new cancer agents.

It presented its findings on investigational compounds AMG 386, AMG 470 and AMG 102.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.